Case study: childhood-onset tardive dyskinesia versus choreoacanthocytosis.

A male adolescent presented with aggression, depressed mood, and severe movement disorder that developed at age 5 after exposure to neuroleptics. Evaluation revealed acanthocytes in his blood, which led to a differential diagnosis of tardive dyskinesia versus choreoacanthocytosis. However, this is unusually young age of onset for these conditions. Differential diagnosis, medication management of the movement disorder, and pathophysiological mechanisms in tardive dyskinesia and choreoacanthocytosis are discussed.

[1]  J. Overall,et al.  Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[2]  T. White,et al.  Caudate Nucleus Morphology in Tardive Dyskinesia , 1996, British Journal of Psychiatry.

[3]  R. Buchanan,et al.  Basal ganglia pathology in schizophrenia and tardive dyskinesia: an MRI quantitative study. , 1994, The American journal of psychiatry.

[4]  K. Igarashi,et al.  MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies. , 1994, The Journal of pharmacology and experimental therapeutics.

[5]  W. Dobyns,et al.  Benign hereditary chorea. , 1993, Pediatric neurology.

[6]  P. Lavori,et al.  Vitamin E treatment of tardive dyskinesia. , 1993, The American journal of psychiatry.

[7]  Werry Js.  Long-term drug use in psychiatric disorders in children. Facts, controversies and the future. , 1993 .

[8]  T. Feinberg,et al.  Diagnostic tests for choreoacanthocytosis , 1991, Neurology.

[9]  Sprague Rl,et al.  Reliability, validity, and a total score cutoff for the dyskinesia identification system: condensed user scale (DISCUS) with mentally ill and mentally retarded populations. , 1991 .

[10]  J. Cadet,et al.  Chronic treatment with prolixin causes oxidative stress in rat brain , 1990, Biological Psychiatry.

[11]  V. Marchesi,et al.  Full-length sequence of the cDNA for human erythroid beta-spectrin. , 1990, The Journal of biological chemistry.

[12]  V. Marchesi,et al.  Heterogeneity of mRNA and protein products arising from the protein 4.1 gene in erythroid and nonerythroid tissues , 1990, The Journal of cell biology.

[13]  R. Hardie,et al.  Acanthocytosis and neurological impairment--a review. , 1989, The Quarterly journal of medicine.

[14]  V. Bennett.  The membrane skeleton of human erythrocytes and its implications for more complex cells. , 1985, Annual review of biochemistry.

[15]  T. Bird,et al.  Familial degeneration of the basal ganglia with acanthocytosis: A clinical, neuropathological, and neurochemical study , 1978, Annals of neurology.

[16]  J. Estes,et al.  Hereditary neurological disease with acanthocytosis. A new syndrome. , 1968, Archives of neurology.